{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:57Z","timestamp":1787763717812,"version":"build-2784847793"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166606","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T19:40:56Z","timestamp":1481312456000},"page":"e0166606","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients"],"prefix":"10.1371","volume":"11","author":[{"given":"Xiaolun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna L.","family":"Knoble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-2077","authenticated-orcid":false,"given":"Ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando N.","family":"Aguila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell W.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"S Krishnan","year":"2007","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jso.21954","article-title":"Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer","volume":"104","author":"M Patel","year":"2011","journal-title":"J Surg Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"EA Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"E Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2004.01.003","article-title":"A treatment planning study evaluating a &apos;simultaneous integrated boost&apos; technique for accelerated radiotherapy of stage III non-small cell lung cancer","volume":"45","author":"ML Dirkx","year":"2004","journal-title":"Lung Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.prro.2013.06.004","article-title":"Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus","volume":"4","author":"SK Jabbour","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"ref7","first-page":"241","article-title":"AJCC Cancer Staging Manual","year":"2010"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2307\/2983604","article-title":"Contingency table involving small numbers and the X<sup>2<\/sup> test","volume":"1","author":"F Yates","year":"1934","journal-title":"J Royal Stat Soc"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"MH Katz","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1245\/s10434-010-1460-y","article-title":"Borderline resectable pancreatic cancer: what have we learned and where do we go from here?","volume":"18","author":"MH Katz","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","article-title":"Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer","volume":"258","author":"H Takahashi","year":"2013","journal-title":"Ann Surg"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"JD Murphy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/cncr.28117","article-title":"A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer","volume":"119","author":"EJ Kim","year":"2013","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"S Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2005.03.032","article-title":"Identification of bronchioalveolar stem cells in normal lung and lung cancer","volume":"212","author":"CF Kim","year":"2005","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells\u2014perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"MF Clarke","year":"2006","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0360-3016(93)90371-2","article-title":"Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials","volume":"27","author":"JD Cox","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2005.03.037","article-title":"Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience","volume":"63","author":"M Machtay","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.surg.2011.07.006","article-title":"Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials","volume":"150","author":"MM Assifi","year":"2011","journal-title":"Surgery"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2013.12.030","article-title":"Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer","volume":"88","author":"NF Esnaola","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T03:20:31Z","timestamp":1718940031000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166606"}},"subtitle":[],"editor":[{"given":"Keping","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166606","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,9]]}}}